Early benefit assessments Archives — Page 6 of 10 — German Market Access

G-BA decisions from 12 May 2023

Here are the G-BA decisions from the G-BA meeting held on 12 May 2023 on the early benefit assessments of Tezpire, Adtralza

Here are the G-BA decisions from the G-BA meeting held on 20 April 2023 on the early benefit assessments of Ultomiris, Genvoya,

Since 2020, the G-BA can request real-world evidence data collection in Germany. However, so far this was only implemented for one product,

Last week, I wrote about Janssen’s withdrawal of the lung cancer drug Rybrevant (amivantamab) from the German market. Just a week later,

On 25 August 2022, Janssen has announced that they have withdrawn the lung cancer drug Rybrevant (amivantamab) from the German market with